India’s apex drug regulator is set to remove the requirement for pharmaceutical exporters to obtain an Export No Objection Certificate (NOC) for shipments destined for countries recognised as having Stringent Regulatory Authorities (SRAs), a move expected to streamline trade and boost competitiveness in global markets.
At the 11th Global Pharmaceutical Quality Summit, the Drugs Controller General of India (DCGI) announced that the requirement for exporters to secure an NOC before sending drugs to major markets — including the US, UK, EU, Japan, Australia and Canada — will be discontinued. Under the updated system, exporters will only need to submit a notification and will receive an auto-generated acknowledgment from the regulator.
Industry experts welcomed the reform as a significant reduction in procedural delays that have long burdened Indian drug manufacturers and slowed shipment clearances. Previously, exporters had to apply for an annual NOC from the Central Drugs Standard Control Organisation (CDSCO), even when the importing country already had its own regulatory approval processes, a requirement that critics said often duplicated efforts and increased compliance costs.
The easing of the NOC norm aligns with broader regulatory reforms aimed at improving ease of doing business for India’s pharmaceutical sector. Alongside this change, the regulator has already reduced review timelines for clinical research approvals and eliminated certain low-risk authorisation requirements — part of a wider shift toward risk-calibrated oversight that focuses regulatory resources on areas with higher public health implications.
The reform also comes as India’s drug regulator intensifies quality enforcement across the industry, including upgraded compliance inspections and revised manufacturing standards, to enhance global confidence in Indian pharmaceutical exports.
Pharma exporters hope the removal of the export NOC requirement will cut administrative bottlenecks and reinforce India’s position as a leading global supplier of medicines, particularly in competitive markets with stringent regulatory norms.
